JC Watt shares his story on why he started this fundraiser for Alzheimer's and its new location at the Star Centre in Havre ...

Cassava Sciences has officially ended development of simufilam in Alzheimer’s disease, marking the end of a tumultuous era ...

While investigations into the drug are stopping in Alzheimer’s disease, the therapy is now being evaluated in TSC-related ...

Wong’s vision for the future is ambitious yet practical. He hopes to make volunteering more accessible and inclusive, ...

If you’ve ever watched Shark Tank, you probably know Barbara Corcoran. On the show, she invests in businesses, but away from ...

NEW YORK (Reuters) -The biotechnology company Cassava Sciences failed on Wednesday to end a malicious prosecution lawsuit by ...

The saga of Cassava Sciences' development of Alzheimer's disease therapy simufilam has come to its dismal end. The company has reported top-line data from a second phase 3 trial of the drug ...

Cassava Sciences (NASDAQ:SAVA) said Tuesday it will shut down its Alzheimer's disease program by the end of the second quarter after another Phase 3 trial failure for simufilam, its lead ...

For years, entrepreneur Barbara Corcoran has put her skills at the forefront of investing in optimistic businesses through ...

Monetary gifts in the fourth quarter of 2024 were up 21 percent, compared with the third quarter, according to the latest ...

Hospice care typically involves a multidisciplinary team of healthcare professionals, each specializing in different aspects ...

Cassava Sciences is ending simufilam development for Alzheimer's after Phase 3 trials failed. The company is shifting focus to potential seizure treatments.